39 completed, 13 active not recruiting, 9 terminated, 2 recruiting. 66 Phase 2, 6 Phase 1, 4 Phase 3.
Follow cediranib: new trials by email Literature Review of cediranib trials Research Report on cediranib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents Biospecimen Collection, Cediranib Maleate, Computed Tomography - Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 120 | 2021-06-10 | 2026-10-22 |
| Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer Cediranib, Ceralasertib, Olaparib - Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 60 | 2020-07-28 | 2026-09-14 |
| WIRE - Novel Treatments in Renal Cell Cancer Olaparib, Cediranib, Volrustomig - Renal Cell Cancer | Phase 2 | Recruiting | CCTU- Cancer Theme | 134 | 2020-07-27 | 2026-09-25 |
| Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma Cediranib Maleate, Durvalumab - Uveal Melanoma, Metastatic Cancer | Phase 2 | Withdrawn | Grupo Español Multidisciplinar de Melanoma | 2020-05-01 | 2020-06-02 | |
| Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors Durvalumab, Olaparib, Cediranib - Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma | Phase 2 | Active not recruiting | University Health Network, Toronto | 90 | 2019-04-08 | 2026-10-05 |
| A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer Cediranib, Olaparib - Cervical Cancer | Phase 2 | Active not recruiting | The Clatterbridge Cancer Centre NHS Foundation Trust | 79 | 2018-10-09 | 2025-02-26 |
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 288 | 2018-09-27 | 2026-10-22 |
| Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? Paclitaxel, Cediranib, Olaparib - Carcinosarcoma, Endometrial Neoplasms | Phase 2 | Unknown | University of Manchester | 124 | 2018-05-17 | 2022-03-02 |
| Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer Cediranib - Bowel Obstruction, Ovarian Cancer | Phase 2 | Completed | Prof Gordon Jayson | 30 | 2018-05-14 | 2026-06-15 |
| Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer Carboplatin, Cediranib, Cediranib Maleate - Extensive Stage Lung Small Cell Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 9 | 2018-03-30 | 2023-10-17 |
| Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy Durvalumab, Danvatirsen, Ceralasertib - Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | AstraZeneca | 528 | 2017-12-18 | 2025-10-27 |
| Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma Bevacizumab, Cediranib, Cediranib Maleate - Recurrent Glioblastoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 70 | 2017-12-07 | 2026-09-15 |
| Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer Cediranib, Olaparib - Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 90 | 2017-08-11 | 2026-07-31 |
| Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib Paclitaxel, Cediranib, Olaparib - Ovarian Neoplasms | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 123 | 2017-06-12 | 2025-01-10 |
| Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer Olaparib, Cediranib, Paclitaxel - Ovarian Cancer | Phase 2 | Completed | University of Oxford | 139 | 2017-03-09 | 2024-01-23 |
| Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer cediranib and olaparib - Recurrent Platinum Resistant Ovarian Cancer | Phase 2 | Completed | AstraZeneca | 62 | 2017-01-17 | 2022-03-08 |
| A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors 18F-Fluoromisonidazole, Cediranib Maleate, Laboratory Biomarker Analysis - Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 122 | 2016-08-31 | 2026-09-25 |
| Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer Biopsy Procedure, Biospecimen Collection, Cediranib Maleate - Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 70 | 2016-05-23 | 2026-09-29 |
| Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer Cediranib, Cediranib Maleate, Computed Tomography - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 582 | 2016-05-03 | 2026-10-01 |
| Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... Olaparib, Cediranib, Durvalumab - Colorectal Neoplasms, Breast Neoplasms | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 268 | 2015-06-29 | 2026-10-16 |
Showing 20 of 66. Sign in to see all of them.
Ovarian Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (6) · Fallopian Tube Neoplasms (6) · Colorectal Neoplasms (5) · Glioblastoma (5) · Neoplasms (5) · Breast Neoplasms (4) · Carcinoma, Renal Cell (4) · Gliosarcoma (4) · Prostatic Neoplasms (4) · Carcinoma, Hepatocellular (3) · Mesothelioma, Malignant (3) · Sarcoma (3) · Sarcoma, Alveolar Soft Part (3) · Solitary Fibrous Tumor, Pleural (3)
National Cancer Institute (NCI) (38) · AstraZeneca (10) · Alliance for Clinical Trials in Oncology (2) · University College, London (2) · University Health Network, Toronto (2) · CCTU- Cancer Theme (1) · Grupo Español Multidisciplinar de Melanoma (1) · Institute of Cancer Research, United Kingdom (1) · M.D. Anderson Cancer Center (1) · Mario Negri Institute for Pharmacological Research (1) · NCIC Clinical Trials Group (1) · Prof Gordon Jayson (1) · Radboud University Medical Center (1) · The Clatterbridge Cancer Centre NHS Foundation Trust (1) · University of Glasgow (1)
United States (43) · United Kingdom (15) · Canada (14) · Spain (5) · Australia (4) · Germany (4) · Austria (3) · France (3) · Italy (3) · Netherlands (3) · Belgium (2) · Brazil (2) · Czechia (2) · Israel (2) · Japan (2)
Jane Robertson (4) · Alice P Chen, M.D. (2) · Jane Robertson, MD (2) · Joseph W Kim (2) · Joyce F Liu (2) · Jung-min Lee (2) · Alex A. Adjei, MD, PhD (1) · Amit Oza, M.D. (1) · Andrew Clamp (1) · Andrew Zhu (1) · Anne S Tsao (1) · Banu Arun (1) · Bert H. O'Neil, MD (1) · Bijoyesh Mookerjee, MD (1)
PMID 25113840, PMID 37185961, PMID 18398152, PMID 19203899, PMID 19917841, PMID 20458050, PMID 22285180, PMID 22831987, PMID 23232491, PMID 23362324, PMID 23419134, PMID 23630200, PMID 23801303, PMID 23810467, PMID 24309981, PMID 24714778, PMID 24788563, PMID 25218906, PMID 25895616, PMID 26179201, PMID 26802156, PMID 27232884, PMID 30514390, PMID 30679026, PMID 30738795, PMID 31160249, PMID 31345267, PMID 31378656, PMID 31386610, PMID 31502400, PMID 33452192, PMID 33842889, PMID 34794412, PMID 35063281, PMID 35170751, PMID 36256912, PMID 36302173, PMID 38127487, PMID 38197800, PMID 38351187, PMID 38981998, PMID 39361946, PMID 41360639, PMID 41369900, PMID 41881502, PMID 41887529, PMID 42339309, PMID 42386344, PMID 42820295
N01CM62201 (5), U10CA180868 (5), UM1CA186709 (4), 2016 (3), N01CM00071 (3), N01CM62203 (3), N01CM62209 (3), P30CA006516 (3), U01CA062490 (3), N01CM00038 (2), N01CM62205 (2), P30CA014599 (2), P30CA015083 (2), P30CA022453 (2), U01CA062487 (2)